TY - JOUR AU - Coiffier, B. AU - Lepage, E. AU - Briere, J. AU - Herbrecht, R. AU - Tilly, H. AU - Bouabdallah, R. PY - 2002 DA - 2002// TI - CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma JO - N Engl J Med VL - 346 UR - https://doi.org/10.1056/NEJMoa011795 DO - 10.1056/NEJMoa011795 ID - Coiffier2002 ER - TY - JOUR AU - Coiffier, B. AU - Thieblemont, C. AU - Neste, E. AU - Lepeu, G. AU - Plantier, I. AU - Castaigne, S. PY - 2010 DA - 2010// TI - Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-03-276246 DO - 10.1182/blood-2010-03-276246 ID - Coiffier2010 ER - TY - JOUR AU - Gisselbrecht, C. AU - Glass, B. AU - Mounier, N. AU - Singh Gill, D. AU - Linch, D. C. AU - Trneny, M. PY - 2010 DA - 2010// TI - Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.1618 DO - 10.1200/JCO.2010.28.1618 ID - Gisselbrecht2010 ER - TY - JOUR AU - Elstrom, R. L. AU - Martin, P. AU - Ostrow, K. AU - Barrientos, J. AU - Chadburn, A. AU - Furman, R. PY - 2010 DA - 2010// TI - Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies JO - Clin Lymphoma Myeloma Leuk VL - 10 UR - https://doi.org/10.3816/CLML.2010.n.030 DO - 10.3816/CLML.2010.n.030 ID - Elstrom2010 ER - TY - JOUR AU - Cerchietti, L. AU - Leonard, J. P. PY - 2013 DA - 2013// TI - Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP JO - Hematology Am Soc Hematol Educ Program VL - 2013 ID - Cerchietti2013 ER - TY - JOUR AU - Shaknovich, R. AU - Geng, H. AU - Johnson, N. A. AU - Tsikitas, L. AU - Cerchietti, L. AU - Greally, J. M. PY - 2010 DA - 2010// TI - DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-05-285320 DO - 10.1182/blood-2010-05-285320 ID - Shaknovich2010 ER - TY - JOUR AU - Clozel, T. AU - Yang, S. AU - Elstrom, R. L. AU - Tam, W. AU - Martin, P. AU - Kormaksson, M. PY - 2013 DA - 2013// TI - Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma JO - Cancer Discov VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-13-0117 DO - 10.1158/2159-8290.CD-13-0117 ID - Clozel2013 ER - TY - JOUR AU - O'Connor, O. A. AU - Heaney, M. L. AU - Schwartz, L. AU - Richardson, S. AU - Willim, R. AU - MacGregor- Cortelli, B. PY - 2006 DA - 2006// TI - Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.01.9679 DO - 10.1200/JCO.2005.01.9679 ID - O'Connor2006 ER - TY - JOUR AU - Crump, M. AU - Coiffier, B. AU - Jacobsen, E. D. AU - Sun, L. AU - Ricker, J. L. AU - Xie, H. PY - 2008 DA - 2008// TI - Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdn031 DO - 10.1093/annonc/mdn031 ID - Crump2008 ER - TY - JOUR AU - Bird, A. P. AU - Wolffe, A. P. PY - 1999 DA - 1999// TI - Methylation-induced repression—belts, braces, and chromatin JO - Cell VL - 99 UR - https://doi.org/10.1016/S0092-8674(00)81532-9 DO - 10.1016/S0092-8674(00)81532-9 ID - Bird1999 ER - TY - JOUR AU - Jones, P. L. AU - Veenstra, G. J. AU - Wade, P. A. AU - Vermaak, D. AU - Kass, S. U. AU - Landsberger, N. PY - 1998 DA - 1998// TI - Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription JO - Nat Genet VL - 19 UR - https://doi.org/10.1038/561 DO - 10.1038/561 ID - Jones1998 ER - TY - JOUR AU - Chou, T. C. AU - Talalay, P. PY - 1984 DA - 1984// TI - Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors JO - Adv Enzyme Regul VL - 22 UR - https://doi.org/10.1016/0065-2571(84)90007-4 DO - 10.1016/0065-2571(84)90007-4 ID - Chou1984 ER - TY - JOUR AU - Cheson, B. D. AU - Horning, S. J. AU - Coiffier, B. AU - Shipp, M. A. AU - Fisher, R. I. AU - Connors, J. M. PY - 1999 DA - 1999// TI - Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group JO - J Clin Oncol VL - 17 ID - Cheson1999 ER - TY - JOUR AU - Juweid, M. E. AU - Wiseman, G. A. AU - Vose, J. M. AU - Ritchie, J. M. AU - Menda, Y. AU - Wooldridge, J. E. PY - 2005 DA - 2005// TI - Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.891 DO - 10.1200/JCO.2005.01.891 ID - Juweid2005 ER - TY - JOUR AU - Kalac, M. AU - Scotto, L. AU - Marchi, E. AU - Amengual, J. AU - Seshan, V. E. AU - Bhagat, G. PY - 2011 DA - 2011// TI - HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-02-336891 DO - 10.1182/blood-2011-02-336891 ID - Kalac2011 ER - TY - JOUR AU - Kirschbaum, M. AU - Gojo, I. AU - Goldberg, S. L. AU - Bredeson, C. AU - Kujawski, L. A. AU - Yang, A. PY - 2014 DA - 2014// TI - A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome JO - Br J Haematol VL - 167 UR - https://doi.org/10.1111/bjh.13016 DO - 10.1111/bjh.13016 ID - Kirschbaum2014 ER - TY - JOUR AU - Silverman, L. AU - Verma, A. AU - Odchimar-Reissig, R. AU - Feldman, E. AU - Navada, S. AU - Demakos, E. P. PY - 2013 DA - 2013// TI - A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of study 6898 of the New York Cancer Consortium JO - Blood (ASH Annu Meet Abstr) VL - 122 ID - Silverman2013 ER - TY - JOUR AU - Stathis, A. AU - Hotte, S. J. AU - Chen, E. X. AU - Hirte, H. W. AU - Oza, A. M. AU - Moretto, P. PY - 2011 DA - 2011// TI - Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin’s lymphomas JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-1893 DO - 10.1158/1078-0432.CCR-10-1893 ID - Stathis2011 ER - TY - JOUR AU - Fandy, T. E. H. AU - Herman, J. G. AU - Kerns, P. AU - Jiemjit, A. AU - Sugar, E. A. AU - Choi, S. H. PY - 2009 DA - 2009// TI - Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies JO - Blood VL - 13 UR - https://doi.org/10.1182/blood-2009-02-203547 DO - 10.1182/blood-2009-02-203547 ID - Fandy2009 ER - TY - JOUR AU - Yee KM, M. D. AU - Brandwein, J. AU - Schimmer, A. AU - Schuh, A. AU - Gupta, V. AU - Messner, H. A. PY - 2007 DA - 2007// TI - A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia (AML). [abstract] JO - Blood (ASH Annu Meet Abstr) VL - 110 ID - Yee KM2007 ER - TY - JOUR AU - Ravandi, F. AU - Faderl, S. AU - Thomas, D. AU - Burger, J. AU - Koller, C. AU - Garcia-Manero, G. PY - 2007 DA - 2007// TI - Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia JO - Blood (ASH Annu Meet Abstr) VL - 110 ID - Ravandi2007 ER -